Overview

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Treatments:
apatinib